Skip to content
Open access

Naringenin as a dual-target modulator of RAGE–NF-κB signaling and Aβ fibrillization in Alzheimer’s disease: integrated computational and experimental analyses

Aug 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 47 references
Medicine

TL;DR

NAR reduced Aβ42-induced NF-κB activation in RAGE-positive C6 cells, protected SH-SY5Y neurons from Aβ42 toxicity, and inhibited Aβ42 fibrillization in vitro, producing non-seeding aggregates consistent with impaired fibril formation, and attenuated rotenone-induced α-synuclein-associated cellular stress.

Abstract

Introduction Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by the accumulation and aggregation of β-amyloid (Aβ) and chronic neuroinflammation mediated by the receptor for advanced glycation end products (RAGE). Current therapeutic candidates targeting RAGE signaling or Aβ aggregation continue to face challenges, including off-target toxicity, poor blood-brain barrier (BBB) penetration, and limited multi-target efficacy. Methods Naringenin (NAR), a naturally occurring flavanone polyphenol prioritized through structure-based virtual screening and preliminary biological evaluation, was selected for further mechanistic investigation as a potential dual-target modulator of RAGE-associated inflammatory signaling and Aβ42 fibrillization. Results Molecular docking analyses showed that NAR interacts with the RAGE interface (PDB: 6XQ3) via π-cation interactions with ARG_98 and LYS_110 (docking score: −5.072 kcal/mol). At the Aβ fibril (PDB: 2MXU), NAR showed a superior docking score than ALZ-801 (valiltramiprosate), involving hydrogen bonding and π–π stacking with HIS_A14 (docking score: −8.098 kcal/mol). 100 ns molecular dynamics simulations supported the stability of these binding modes, with RMSD and RMSF values within acceptable ranges. MM-GBSA rescoring indicated competitive predicted binding free energies (ΔGBind: −30.260 kcal/mol at RAGE; −220.162 kcal/mol at the fibril, compared to ALZ- 801’s −214.482 kcal/mol), influenced by electrostatic and hydrophobic interactions. Per-residue energy decomposition indicated PHE_20 (−9.10 kcal/ mol) as the dominant hotspot residue, alongside ARG_98 (−4.71 kcal/mol) and LYS_52 (−3.96 kcal/mol) as key RAGE anchors. In silico ADMET profiling suggested favorable predicted BBB accessibility (score: 0.001), Caco-2 permeability, Lipinski compliance, and a more favorable predicted cardiac safety profile (hERG: 0.145) relative to V6Y. Experimentally, NAR reduced Aβ42-induced NF-κB activation in RAGE-positive C6 cells, protected SH-SY5Y neurons from Aβ42 toxicity, and inhibited Aβ42 fibrillization in vitro, producing non-seeding aggregates consistent with impaired fibril formation, and attenuated rotenone-induced α-synuclein-associated cellular stress. Discussion Collectively, these findings support further investigation of NAR as a mechanistically plausible multi-target candidate for protein aggregation and RAGE-associated inflammatory signaling in neurodegenerative disease models.

Read PDF

Similar papers

Open access Sep 2026

Targeting TLR4/NF-κB/NLRP3 signaling with 6-hydroxyflavanone mitigates amyloid-β-induced Alzheimer's disease in mice.

6-OH-F ameliorates Aβ-induced cognitive impairment by attenuating oxidative stress, neuroinflammation, and pyroptotic signaling, potentially through modulation of the TLR4/NF-κB/NLRP3 pathway, highlighting its therapeutic potential in Alzheimer's disease.

Debarati Rakshit, Mohit Nema, Awanish Mishra · 0 citations
Open access Sep 2026

Mapping the Ligand Binding Landscape of Nurr1 (NR4A2): Computational Characterization of Small-Molecule Interactions in Alzheimer’s Disease Pathway

This project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.

Ji-Ya Zhou · 0 citations
Sep 2026

Rational design, synthesis, and biological evaluation of indole-piperazine based α-ketoamide derivatives as dual Aβ and tau aggregation modulators for Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by pathological aggregation of amyloid-β (Aβ) and tau proteins, representing two major hallmarks of disease progression. Targeting both aggregation pathways simultaneously offers a promising therapeutic strategy. Building upon our previo...

Bhanuranjan Das, Anurag T. K. Baidya, Deepak Chouhan et al. · 0 citations
Sep 2026

AI-guided discovery of a brain-penetrant LILRB4 inhibitor active in microglial and 5xFAD models of Alzheimer's disease.

In human induced pluripotent stem cell-derived microglia, compound 4 reduced SHP1/2 phosphorylation, attenuated NF-κB activation and IL-1β secretion, and restored Aβ uptake without compromising cell viability, and the compound exhibited oral bioavailability and brain penetration.

S. Abdel-Rahman, Moustafa T. Gabr · 0 citations
Aug 2026

Computational Screening of Columbianadin-Derived Furanocoumarins as Multitarget Neurotherapeutics Against MAO-B, AChE, and BACE1 For Alzheimer's Disease

Background: Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by multiple pathological pathways, including monoamine oxidase activity, cholinergic dysfunction, and amyloid-β peptide accumulation. Developing multi-targeted neurotherapeutics has emerged as a promising approach to address this...

Mohammad Yasir, Jeevan Patra, I. Tayubi · 0 citations
Aug 2026

DFT analysis of gamma-secretase interactions with potential inhibitors: therapeutic for Alzheimer's disease.

In this study, molecular-level insights are provided into the interaction mechanisms of γ-secretase inhibitors, contributing to a better understanding of structure-energy relationships that are essential for the rational design of more selective and effective therapeutic agents for Alzheimers disease.

W. S. Clemente, K. S. Bezerra, E. Matias et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.